RNA nasal spray: A groundbreaking innovation in treating memory loss and anxiety, offering new hope for more effective and non-invasive therapies.

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Ebglyss provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients...

Ebglyss provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients...

Learn how sensory neurons and immune cells interact to trigger allergic reactions and explore new therapeutic pathways for preventing allergies.

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.